Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Natera Inc (NQ: NTRA )

120.50 -1.90 (-1.55%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 993,821
Open 120.76
Bid (Size) 112.00 (1)
Ask (Size) 125.70 (1)
Prev. Close 122.40
Today's Range 118.28 - 121.45
52wk Range 36.90 - 133.54
Shares Outstanding 123,681,432
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Evaluating Natera: Insights From 10 Financial Analysts
Via Benzinga
Blue Skies, New Highs Remain Disciplined And Do Not Chase Extended Ideas
It is Fall clean up time. Sell lagging and sagging companies. 
Via Talk Markets

Performance

YTD
+94.61%
+94.61%
1 Month
-2.46%
-2.46%
3 Month
+14.21%
+14.21%
6 Month
+35.99%
+35.99%
1 Year
+200.65%
+200.65%

More News

Read More
Why the high growth investor may take a look at NATERA INC (NASDAQ:NTRA).
Via Chartmill
A Biotech Breakout Will Be Led By Small Caps
Via Talk Markets
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase
From Natera, Inc.
Via Business Wire
Analyst Scoreboard: 9 Ratings For Natera
Via Benzinga
Peering Into Natera's Recent Short Interest
Via Benzinga
Peeling Back The Layers: Exploring Natera Through Analyst Insights
Via Benzinga
Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
From Natera, Inc.
Via Business Wire
First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
From Natera, Inc.
Via Business Wire
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
From Natera, Inc.
Via Business Wire
Forecasting The Future: 6 Analyst Projections For Natera
Via Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
Shopify, Palantir And Uber Are Among Top 10 Large Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
Via Benzinga
NTRA Stock Earnings: Natera Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Natera Reports Second Quarter 2024 Financial Results
From Natera, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today
Via Benzinga
(NTRA) - Analyzing Natera's Short Interest
Via Benzinga
Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Natera, Inc.
Via Business Wire
Natera to Report its Second Quarter 2024 Results on August 8, 2024
From Natera, Inc.
Via Business Wire
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
From Natera, Inc.
Via Business Wire
Here's How Much You Would Have Made Owning Natera Stock In The Last 5 Years
Via Benzinga
The 3 Best Gene Editing Stocks to Buy in July 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.